New eczema shot tested for safety in first human trial
NCT ID NCT05114889
Summary
This was a first-step safety study for a new injectable drug called BSI-045B, intended to treat atopic dermatitis (eczema). Researchers tested single and multiple doses in 54 healthy volunteers and a small group of patients with moderate-to-severe eczema to see how safe and tolerable the drug was. The main goal was to check for side effects and see how the drug moves through the body before testing if it can improve skin symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.